tbuckley/cabot-search huggingface dataset:
P5-03-02: Aurora A Is Closely Linked to an Aggressive Phenotype of Breast Cancer.
Authors: Y Yamamoto, M Ibusuki, K Murakami, H Iwase
Journal: Cancer Research (2011)

Abstract (Purpose) Aurora A, a mitotic serine/threonine kinase, is involved in important process of mitotic progression. The aim of this study is to clarify characteristics of breast cancer with Aurora A expression. (Methods) We examined, by immunohistochemical analysis, the expression of Aurora A in primary invasive breast cancer. We also investigated the correlation between expression of Aurora A and clinicopathological and biological factors. In addition, we studied the prognostic value of Aurora A in breast cancer. (Results) In 215 cases of invasive cancer examined, Aurora A was mainly identified in tumor nuclei. Aurora A expression was detected in 67 (31.2%) cases. Expression of Aurora A was correlated with tumor size (p=0.002), lymph node metastasis (p=0.002), tumor stage (p=0.04) and histological grade (p=0.0031). Aurora A expression was also associated with hormone receptor negativity (p=0.0001), and increased levels of HER2 (p&amp;lt;0.0028), Ki67 (p&amp;lt;0.0001), HIF-1alpha (p&amp;lt;0.0001), VEGF (p=0.007), COX-2 (p=0.002) and p53 (p&amp;lt;0.0001). Patients who had increased Aurora A levels in their tumor showed shorter disease-free survival (DFS) (p&amp;lt;0.0001) and overall survival (OS) (p=0.0002) than those lacking Aurora A in univariate analysis. However, in multivariate analysis of DFS and OS, Aurora A was not identified an independent prognostic factor. (Conclusion) Aurora A expression was significantly correlated with tumor burden, poorly differentiation, negativity of hormone receptors, tumor cell proliferation, and tumor angiogenesis. These findings suggest that Aurora A was closely related with an aggressive phenotype in breast cancer. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-03-02.
False-Positive Suspicion of a Thyroid Metastatic Lesion by In-111 Pentetreotide Uptake in a Toxic Nodular Goiter
Authors: MOHAMED GACI, OLIVIER MOREL, ANN- MARIE SULTAN, PHILIPPE GIRAUD, JEAN- PIERRE MURATET, ERIK GAMELIN, PIERRE JALLET
Journal: Clinical Nuclear Medicine (2001)

GACI, MOHAMED M.D.; MOREL, OLIVIER M.D.; SULTAN, ANN- MARIE M.D.; GIRAUD, PHILIPPE M.D.; MURATET, JEAN- PIERRE M.D.; GAMELIN, ERIK M.D., AND; JALLET, PIERRE M.D. Author Information
645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT
Authors: A. Sanyal, K.D. Mullen, N.M. Bass, T. Frederick, F. Poordad, J. Hee, K. Merchant, E. Bortey, W.P. Forbes
Journal: Journal of Hepatology (2012)
The Use of Radioactive Iodine in the Detection of Thyroid Dysfunction
Authors: W. W. Drummy
Journal: New England Journal of Medicine (1953)

THE increasing use of radioiodine for the evaluation of thyroid function1 2 3 prompts the recording of the experience gained with a relatively simple method in 2000 patients. Although a number of procedures using radioactive iodine and measuring different parameters of thyroid function have been described, none of these are free from error or absolutely reliable. The method employed in this study has been widely used and involves measurement of accumulation in the thyroid region in the twenty-four-hour period after the oral administration of a known amount of radioiodine. The routine application of this technic over a four-year period has led to . . .
Case 75-1962
Authors: Howard Ulfelder, Benjamin Castleman
Journal: New England Journal of Medicine (1962)

Presentation of CaseA sixty-one-year-old woman was referred to the hospital because of a pelvic mass.The patient had enjoyed excellent health until five months before entry, when she consulted a physician because of a cough, rhinorrhea and fever and was given iron tablets and vitamins for "anemia." Thereafter, a mild fever and cough occurred intermittently, with increasing fatigue, and a subsequent physical examination disclosed a pelvic mass.There was no history of urinary frequency, dysuria, hematuria, change in the bowel habits, melena or abdominal pain. The patient lost 15 pounds in weight during the month before admission, although she . . .
FRI0542 Preferences of maltese patients with rheumatic diseases for information on drug adverse events and shared decision making
Authors: K. Cassar, P.-J. Cassar, S. Bezzina Wettinger, R. Zammit
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Increasing importance is being given to a shared medical decision making (DM) process. However, not all patients desire the same level of participation in medical DM.<sup>1</sup> There are no studies exploring desires of Maltese patients with rheumatic diseases regarding informed consent and medical DM. <h3>Objectives</h3> To explore whether Maltese patients with rheumatic diseases wish to be informed about potentially serious adverse events of corticosteroids, DMARDs and biological agents, and to be involved in the medical DM process. <h3>Methods</h3> Questionnaire completed by Maltese patients attending a Rheumatology Out-Patient Clinic. Aspects covered included Demographic data, Desires for (a) information about disease, (b) Knowledge of drug adverse events (DAEs) (c) involvement in DM Process. <h3>Results</h3> 196 participants; Mean age 62 years; 69% female; 42% had a primary level of education. Participant self-assessment of knowledge of disease: 19% claimed sufficient knowledge (median age 60 years); 42% felt the need to know more (median age 61 years); 38% desired no knowledge since their doctor knew best. The latter tended to be older (p=0.002, median age 65 years). Desire for Knowledge of DAEs: 56% wanted information about all DAEs; 34% wanted some information and 16% wanted no information. The latter tended to be older (p=0.004, median age 65 years), and had a lower level of education (p=0.06). Desire for a Choice of Treatment and Involvement in DM Process: 54% wanted rheumatologist to decide on treatment; 30% wanted a discussion on best treatment options; 16% preferred to choose treatment without physician indicating best option. 50% of females compared to 36% of males wanted at least some level of involvement in DM process (p=0.058). This group also tended to be younger (p=0.002, median age 60 vs 65 years). 71% of those with a post-secondary/tertiary level of education wished to participate in the DM process compared to 41% of those with a secondary school level of education or less (p=0.02). 73% of those who did not want to be involved in the DM process still wished to be informed about DAEs at least to some degree. <h3>Conclusions</h3> Information on DAEs is important for Maltese patients with rheumatic diseases. However the desire for information is not reflected in a desire for involvement in the DM process. Whilst there are many benefits of shared DM, rheumatologists must do their best to understand and respect patient individual preferences. <h3>References</h3> R Neame et al. Need for Information and for Involvement in Decision Making Among Patients with Rheumatoid Arthritis: A Questionnaire Survey. Arthritis Rheum (Arthritis Care &amp; Res); 2005;53:249–255. <h3>Disclosure of Interest</h3> None Declared
PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia
Authors: Laura Behan, Borislav D. Dimitrov, Claudia E. Kuehni, Claire Hogg, Mary Carroll, Hazel J. Evans, Myrofora Goutaki, Amanda Harris, Samantha Packham, Woolf T. Walker, Jane S. Lucas
Journal: European Respiratory Journal (2016)

Symptoms of primary ciliary dyskinesia (PCD) are nonspecific and guidance on whom to refer for testing is limited. Diagnostic tests for PCD are highly specialised, requiring expensive equipment and experienced PCD scientists. This study aims to develop a practical clinical diagnostic tool to identify patients requiring testing. Patients consecutively referred for testing were studied. Information readily obtained from patient history was correlated with diagnostic outcome. Using logistic regression, the predictive performance of the best model was tested by receiver operating characteristic curve analyses. The model was simplified into a practical tool (PICADAR) and externally validated in a second diagnostic centre. Of 641 referrals with a definitive diagnostic outcome, 75 (12%) were positive. PICADAR applies to patients with persistent wet cough and has seven predictive parameters: full-term gestation, neonatal chest symptoms, neonatal intensive care admittance, chronic rhinitis, ear symptoms, situs inversus and congenital cardiac defect. Sensitivity and specificity of the tool were 0.90 and 0.75 for a cut-off score of 5 points. Area under the curve for the internally and externally validated tool was 0.91 and 0.87, respectively. PICADAR represents a simple diagnostic clinical prediction rule with good accuracy and validity, ready for testing in respiratory centres referring to PCD centres.
Lack of Relation between Culture and Anorexia Nervosa — Results of an Incidence Study on Curaçao
Authors: Hans Wijbrand Hoek, Peter N. van Harten, Daphne van Hoeken, Ezra Susser
Journal: New England Journal of Medicine (1998)

To the Editor: Anorexia nervosa is considered to be a Western-culture–bound syndrome occurring mainly in young, white women. In Western culture, the preoccupation with thinness and sociocultural pressures to diet have been regarded as etiologic factors in the pathogenesis of anorexia nervosa.1 It is thought to be very rare outside the Western world and in black women in industrialized countries.2 Therefore, we hypothesized that we would find no or very few cases of anorexia nervosa in a population-based study on the Caribbean island of Curacao, where overweight is socially acceptable.3 The mean body-mass index (the weight in kilograms divided by . . .
GE-08 * IMPACT OF H3.3K27M MUTATION ON CANCER EPIGENOME
Authors: D. Fang, Z. Zhang
Journal: Neuro-Oncology (2015)

Diffuse intrinsic pontine glioma (DIPG) is an aggressive primary brain tumor found exclusively in children and the median survival for DIPG patients is about one year from diagnosis. Recent studies have uncovered that a somatic mutation in the H3F3A gene, which has been observed in 80% of DIPG cases, is likely a main driver of tumorigenesis. H3F3A encodes histone H3 variant H3.3 that plays an important role in regulating gene expression during development. The predominant mutation at H3F3A leads to amino acid change at lysine (K) 27 residue of H3.3 to methionine (M). In human cells, there are two genes that encode H3.3 and 14 genes that encode histones H3.1 and H3.2. H3.3 differs from H3.1 and H3.2 by four or five amino acids. Lysine 27 is conserved among all these histone H3 proteins. Therefore, it is unknown how H3.3K27M mutation, which occurs at one allele of H3F3A gene, promotes tumorigenesis. We and others have shown that a global loss of H3K27 methylation occurs in DIPG cells with a K27M mutation. H3K27 methylation is catalyzed by the PRC2 lysine methyltransferase and plays an important role in gene silencing during stem cell differentiation and maintenance. We also observed that in addition to the global loss of H3K27me3 which is associated with gene activation, H3K27me3 is still present at the gene promoters of about 800 genes. These genes are enriched in cancer pathways. At this meeting, I will present our recent findings indicating why some gene loci are enriched with H3K27me3 in H3.3K27M mutant tumor lines.
OP0266-PARE Osteoporosis Prevention Project in Estonia: Bone Density Measurements, Patient Counseling, Information Days, Lectures and Materials
Authors: E. Udras, T. Karp
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoporosis is an increasing problem among aging population in Estonia and elsewhere in the world. By assessing the case rate, mortality and financial costs concerning osteoporosis it turns out that these indicators are comparable with the equivalent rates of cardiovascular diseases, asthma, breast cancer and other frequently occurring diseases. In Estonia, 1200 fractures are diagnosed per year caused by osteoporosis, and the treatment costs are approximately 3,2 million euros per year, including work disability, caring and treatment costs. (Osteoporoos. Bela Adojaan et al. Tartu 2001.) Not knowing and ignoring osteoporosis is typical among patients and the whole population, also among medical staff. Therefore Estonian Rheumatsim Association together with four rheumatologists and one orthopaedist from the biggest hospitals of Estonia decided to start an ostoporosis prevention project in March 2012. <h3>Objectives</h3> Short-term goals were to gather as many patients with chronical joint diseases as possible into the project (to regularly control the bone conditions and begin the prevention and treatment at the right time). Long-term goal is to reduce the bone fractures caused by osteoporosis. By reducing the bone fractures patients maintain their ability to work, have a longer life without mobility disability and cope better with everyday life that will lead to the direct decrease of the caring and treatment costs. <h3>Methods</h3> The doctors at the rheumatology centres, GP-s, and other speciality doctors were informed about the project. Patients were informed through patient trainings and doctors. Information was spread out also via speciality magazines. 6 biggest hospitals started with bone density measurements by DEXA method. Patient data was gathered and processed and a satisfaction questionary was conducted. An osteoporosis counseling line was opened on workdays to all questions. Consultants got also one-day training before the start. Informational days about oseoporosis prevention and treatment, riskfactors and diagnosing were organized in different counties in Estonia with approximately 200 participants. Lectures were given during one of the biggest projects (…Walking Day 2012") of Estonian Rheumatism Association and also in some of the biggest hospitals. Also an osteoporosis reference book was released in the end of 2012. <h3>Results</h3> Several articles were published about osteoporosis in different speciality magazines. Many people (patients, specialists etc) were informed about osteoporosis prevention, treatment and diagnosis. Patient data was gathered and processed throgh the bone density measurements. Cooperation was developed further between patient organisations, specialists and patients. The wish is to continue with the project at the same level. <h3>References</h3> Osteoporoos. Bela Adojaan et al. Tartu 2001. <h3>Disclosure of Interest</h3> None Declared
P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab.
Authors: H Eidtmann, K Kittel, M Rezai, H Tesch, HU Ulmer, S Stirnberg, A Belau, C Mau, E Stickeler, I Schrader, P Fasching, CT Salat, A Abdallah, F Holms, K Schwedler, V Nekljudova, S Loibl, Minckwitz G von
Journal: Cancer Research (2011)

Abstract Background: Bevacizumab has been reported to increase the risk of surgical complications, especially in pts treated with neoadjuvant chemotherapy. Methods: In January 2010 it was decided to collect surgical complications prospectively on a specifically developed from. All patients received chemotherapy with epirubicin/cyclophosphamide (EC) followed by docetaxel (T) with or w/o bevacizumab. Patients not responding to the first 4 cycles of EC+/−B were enrolled in another setting. All patients receiving bevacizumab were supposed to be operated at 5 weeks after the last infusion of bevacizumab. Results: Data from 699 patients have been prospectively collected, 329 received EC-T and 370 ECB-TB. Median age was 48 years in both arms. Median tumor size was 30mm in the ET-C arm vs 35mm in the ECB-TB arm (p=0.13). Multifocal or multicentric disease was present in 21% in the EC-T arm vs 22.4% (p=0.74). 36% of the patients received a sentinel node biopsy prior to start of neoadjuvant chemotherapy in both groups. 68.7% of patients received breast conserving therapy in the EC-T arm compared to 71.1% in the ECB-TB arm (p=0.54). The rate of pathological complete response was 19.5% with EC-T compared to 23.2% with ECB-TB (p=0.26). The median time from last CHT+/− bevacizumab to surgery was 29 days in EC-T and 34 days in ECB-TB. Bleeding or hematoma were reported in 6.7% of the patients treated by EC-T and 7.1% with ECB-TB (p=0.88). Wound infections or abscess were reported in 2.5% with EC-T and 3.9% with ECB-TB (p=0.39). Delayed wound healing was reported in 3.4% with EC-T and 6.3% with ECB-TB (p=0.11). Necrosis was reported in 1.9% with EC-T and 2.5% with ECB-TB (p=0.80). Any complication was reported in 11% with EC-T compared to 15.3% with ECB-TB (p=0.12). Conclusion: In general the rate of surgical complications was low. Patients treated with bevacizumab had a numerical increase of surgical complications. However, none of the differences were statistically significant. The intervals from last infusion to surgery as defined by the study protocol appear to be safe. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-14-05.
Ventricular abnormalities in affective disorder: clinical and demographic correlates
Authors: N C Andreasen, V Swayze, M Flaum, R Alliger, G Cohen
Journal: American Journal of Psychiatry (1990)

Ventricle-brain ratio was measured by CT scan in 24 bipolar patients, 27 unipolar patients with major depression, 108 schizophrenic patients, and 75 normal control subjects. The male bipolar patients had significantly larger ventricles, but the depressive patients did not. The findings suggest the possibility that ventricular enlargement in bipolar patients is independent of age, as it appears to be in schizophrenia, whereas in depressed patients it may be related to the aging process. Ventricular enlargement in bipolar patients was not related to relevant clinical correlates, such as response to treatment, history of substance abuse, history of ECT, or cognitive impairment.
Stat Bite: Cancer Treatment Costs
Authors: L. Fintor
Journal: JNCI Journal of the National Cancer Institute (1994)

Stat Bite : Cancer Treatment Costs Get access Lou Fintor Lou Fintor Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 18, 21 September 1994, Page 1380, https://doi.org/10.1093/jnci/86.18.1380 Published: 21 September 1994
RU 486 Enters Limited Clinical Trials
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article RU 486 Enters Limited Clinical Trials Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 8, 15 April 1992, Page 563, https://doi.org/10.1093/jnci/84.8.563 Published: 15 April 1992
Adjuvant Radiotherapy in Periampullary Carcinomas: Dosimetric Comparison of 3DCRT, IMRT and Rapid ARC Plans
Authors: Nandi Moujhuri, Gazi Mahasin, Bhattacharya Jibak, Biswal Subhra, Pramanik Srimanta, Mitra Shila, Saha Subrata
Journal: Annals of Oncology (2014)
Case 5-2011
Authors: Donald S. Kaufman, Anthony L. Zietman, Douglas M. Dahl, Mukesh G. Harisinghani, Chin-Lee Wu
Journal: New England Journal of Medicine (2011)

A 65-year-old man was seen because of hematuria and a tumor in the urethra, 10 years after brachytherapy for prostate cancer. Cystoscopy with biopsy revealed adenocarcinoma of the prostatic urethra. Colonoscopic findings were normal. A procedure was performed.
P847 DAYTIME SLEEPINESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IS LINKED TO INSULIN RESISTANCE, ELEVATED LIVER FUNCTION TESTS AND FIBROSIS
Authors: C. Bernsmeier, D.M. Weisskopf, J. Mosimann, B. Campana, A.C. Meyer-Gerspach, R.E. Steinert, L. Blaser, L. Jeker, L. Terracciano, C. Beglinger, M.H. Heim, C. Cajochen
Journal: Journal of Hepatology (2014)
Imaging Diagnosis of Post-ERCP Focal Pancreatitis Mimicking Pancreatic Carcinoma by Follow-up F-18 FDG PET/CT
Authors: Soo Jeong Yoon, Boeun Lee, Chan H. Park
Journal: Clinical Nuclear Medicine (2010)

Pancreatitis is the most common complication of diagnostic or therapeutic endoscopic retrograde cholangiopancreatography (ERCP). The incidence of clinical post-ERCP pancreatitis is about 5%. The authors describe a case of 60-year-old man who developed an unusual focal, instead of usual diffuse pancreatitis after diagnostic ERCP. F-18 FDG PET/CT in 3 days after ERCP detected focal FDG uptake because of pancreatitis, and the diagnosis was confirmed by spontaneous resolution of the lesion on 1-week follow-up PET/CT study.
Phase II Study of Tailored Dose S-1 Plus Carboplatin Followed by S-1 for Advanced Squamous Cell Lung Cancer
Authors: N. Yuh, K. Komuta, T. Yokoi, S. Yamamoto, S. Minami, T. Shiroyama, T. Hirashima, Y. Namba, T. Kijima, I. Tachibana
Journal: Annals of Oncology (2013)
Abstract 991: Regulation of glucose metabolism by HIF in pancreatic cancer
Authors: Pankaj K. Singh, Vinee Purohit, Nina Chaika, Keith R. Johnson, Michael A. Hollingsworth
Journal: Cancer Research (2011)

Abstract Pancreatic cancer is the fourth leading cause of cancer related deaths with a five-year survival rate of 5.5%. It is characterized by extremely aggressive tumor growth rate and high incidence of metastasis. Like other cancers, pancreatic cancer displays alterations in cellular metabolism, which holds significant promise for better management/cure of the disease. One of the most common and profound biochemical phenotypes of animal and human cancer cells is their ability to metabolize glucose at high rates, even under aerobic conditions. Several oncogenes and tumor suppressors have been implicated in altering tumor cell metabolism in order to facilitate tumor growth and metastasis. The objective of this study was to characterize the role of hypoxia inducible factors (HIF) in glucose metabolism in pancreatic cancer cell lines under normoxic and hypoxic conditions. We screened a panel of pancreatic cancer cell lines for glucose uptake under normoxic and hypoxic conditions. Although the effect of hypoxia on glucose uptake was variable in different pancreatic cancer cell lines, it correlated well with the expression levels of HIF-1alpha and HIF-2alpha. Furthermore, dual knockdown of HIF-1alpha and HIF-2alpha had similar negative effect on growth rate under hypoxic conditions, as did the treatment with glycolysis inhibitor 3-BrPA. These studies suggest that HIF factors regulate growth in pancreatic cancer by regulating glycolysis. Hence, combining strategies to target metabolism along with the strategies to target signal transduction might synergistically aid in diminishing cancer cell growth and invasiveness. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 991. doi:10.1158/1538-7445.AM2011-991
Breast Cancer Screening
Authors: D. M. EDDY
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Breast Cancer Screening Get access DAVID M. EDDY DAVID M. EDDY Center for Health Policy Research and Education Duke UniversityP. O. Box GM, Duke Station Durham, NC 27706 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 3, 1 February 1989, Pages 234–235, https://doi.org/10.1093/jnci/81.3.234 Published: 01 February 1989